Skip to main content
    R

    Revelation Biosciences Inc (REVB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.75
    -0.51 (-12.07%)

    Market Cap: $2.43M

    Last updated: Nov 17, 2026 at 11:00 AM ET

    Revelation Biosciences Inc (REVB) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Revelation Biosciences (REVB) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Revelation Biosciences reported EPS of -$5.92, above the -$6.16 estimate. It beat the EPS estimate in 3 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    54%(13/24)
    Avg Surprise
    +3.45%
    Streak
    1 Q

    Upcoming Estimates

    Reports Feb 24, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$6.20
    Range-$6.45 - -$5.86
    4 analysts
    Revenue Consensus
    N/A
    RangeN/A
    4 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS ConsensusN/A
    RangeN/A
    Revenue Consensus
    N/A
    RangeN/A
    0 analysts

    Next Report

    REVB has an expected report date of Feb 24, 2027.

    Earnings History

    Of the 24 quarters below that had an estimate, REVB beat 13, missed 10 and matched 1. The widest gap in the table came in the quarter ended Mar 31, 2023, when EPS landed 529.23% above the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$5.92-$6.16-$6.58 - -$5.74+3.90%BeatN/A20 up, 0 downNov 5, 2026N/A
    Jun 30, 2026-$0.87-$0.83-$0.88 - -$0.78-4.82%MissN/A20 up, 0 downAug 7, 2026N/A
    Mar 31, 2026-$2.71-$1.15-$1.55 - -$0.75-135.65%MissN/A20 up, 0 downMay 7, 2026N/A
    Dec 31, 2025-$1.65-$1.41-$6.00 - -$1.32-17.02%MissN/A20 up, 0 downFeb 26, 2026N/A
    Sep 30, 2025-$7.08-$5.34-$6.48 - -$4.20-32.58%MissN/A20 up, 0 downNov 6, 2025N/A
    Jun 30, 2025-$7.01-$4.46-$6.15 - -$2.76-57.17%MissN/A22 up, 0 downAug 7, 2025N/A
    Mar 31, 2025-$25.32-$27.52-$30.00 - -$11.28+7.98%BeatN/A21 up, 0 downMay 8, 2025N/A
    Dec 31, 2024-$4.98-$10.32-$15.20 - -$5.44+51.74%BeatN/A21 up, 0 downMar 6, 2025$26964
    Sep 30, 2024-$161.28-$545.28-$908.25 - -$182.42+70.42%BeatN/A20 up, 0 downNov 8, 2024N/A
    Jun 30, 2024-$984.96-$346.56-$435.88 - -$257.31-184.21%MissN/A20 up, 0 downAug 9, 2024N/A
    Mar 31, 2024-$472.32-$1,033.92-$1,728.17 - -$339.87+54.32%Beat-17029.0%20 up, 0 downMay 10, 2024N/A
    Dec 31, 2023-$8.33-$13.77-$13.77 - -$13.77+39.51%BeatN/A11 up, 0 downMar 22, 2024$37574
    Sep 30, 2023-$2,488.78-$1,929.60-$1,960.56 - -$1,499.25-28.98%MissN/A20 up, 0 downNov 9, 2023N/A
    Jun 30, 2023-$1,854.72-$1,872.00N/A+0.92%BeatN/A10 up, 0 downAug 11, 2023N/A
    Mar 31, 2023$2.79-$0.65-$0.65 - -$0.65+529.23%BeatN/A10 up, 0 downMay 22, 2023N/A
    Dec 31, 2022-$12,904.14-$10,080.01N/A-28.02%MissN/A10 up, 0 downMar 30, 2023N/A
    Sep 30, 2022-$12,096.03-$18,144.04N/A+33.33%BeatN/A10 up, 0 downNov 10, 2022N/A
    Jun 30, 2022-$24,192.05-$28,224.06N/A+14.29%BeatN/A10 up, 0 downAug 15, 2022N/A
    Mar 31, 2022-$94,752.20-$28,224.06N/A-235.71%MissN/A10 up, 0 downApr 15, 2022N/A
    Dec 31, 2021-$206,568.84N/AN/AN/AN/AN/AN/AN/ADec 31, 2021N/A
    Sep 30, 2021-$0.42N/AN/AN/AN/AN/AN/AN/AOct 29, 2021N/A
    Jun 30, 2021-$0.73N/AN/AN/AN/AN/AN/AN/AAug 23, 2021N/A
    Mar 31, 2021-$0.16N/AN/AN/AN/AN/AN/AN/AJun 22, 2021N/A
    Dec 31, 2020-$251,590.87N/AN/AN/AN/A-38706388.0%N/AN/AMar 31, 2021N/A
    Sep 30, 2020Not reportedN/AN/AN/ANot reportedN/AN/AN/ANov 16, 2020N/A
    Dec 31, 2019$0.65N/AN/AN/AN/A+10.2%N/AN/AJan 28, 2020$25.07M
    Sep 30, 2019$0.69$0.68$0.66 - $0.69+1.47%Beat+6.2%2N/AOct 24, 2019$24.84M
    Jun 30, 2019$0.65$0.64N/A+1.56%BeatN/A1N/AJul 24, 2019$23.74M
    Mar 31, 2019$0.62$0.61$0.60 - $0.61+1.64%BeatN/A2N/AApr 29, 2019$22.16M
    Dec 31, 2018$0.59$0.61$0.60 - $0.61-3.28%MissN/A2N/AJan 29, 2019$21.45M
    Sep 30, 2018$0.65$0.65$0.65 - $0.650.00%In lineN/A1N/ANov 9, 2018$20.63M
    Last 31 quarters

    Estimates made before a stock split are shown on the same share basis as the reported EPS.

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$41.06, after -$1,623.54 the year before. It was $1.24 for the year ended Dec 31, 2018, the oldest of the 8 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$41.06N/A
    Dec 31, 2024-$1,623.54N/A
    Dec 31, 2023-$4,349.04N/A
    Dec 31, 2022-$143,944.42N/A
    Dec 31, 2021-$206,570.15N/A
    Dec 31, 2020-$251,590.87-9639597.0%
    Dec 31, 2019$2.61+110.5%
    Dec 31, 2018$1.24N/A

    Frequently Asked Questions About REVB

    When is Revelation Biosciences's next earnings date?

    Revelation Biosciences's next earnings report is expected for Feb 24, 2027.

    Did REVB beat earnings estimates last quarter?

    Yes. Revelation Biosciences reported EPS of -$5.92 for the quarter ended Sep 30, 2026, above the -$6.16 estimate, a 3.90% surprise.

    What EPS do analysts expect from REVB next quarter?

    The consensus EPS estimate for Revelation Biosciences for the quarter ending Dec 31, 2026 is -$6.20 from 4 analysts, with estimates from -$6.45 to -$5.86.

    How often does REVB beat earnings estimates?

    Revelation Biosciences beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -22.95%.